SCHEDULE 13G: Goldman Sachs Discloses 6.6% Passive Stake in Silexion Therapeutics
Beneficial Ownership Disclosure
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have disclosed a passive beneficial ownership of 6.6% in Silexion Therapeutics Corp., holding 112,242 ordinary shares as of December 31, 2024.
Summary
- The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, have filed a Schedule 13G indicating beneficial ownership in Silexion Therapeutics Corp.
- As of December 31, 2024, the reporting persons collectively beneficially own 112,242 ordinary shares of Silexion Therapeutics Corp.
- This ownership represents 6.6% of the total outstanding ordinary shares of Silexion Therapeutics Corp.
- The shares are held with shared voting power and shared dispositive power, with no sole voting or dispositive power reported.
- The filing was made under Rule 13d-1(b), signifying that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, indicating a neutral sentiment. It does not contain performance data or forward-looking statements from the issuer.
Positives
- The disclosure of a significant stake by a major institutional investor like Goldman Sachs can be perceived as a vote of confidence in Silexion Therapeutics Corp.
- The filing explicitly states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, which suggests a passive investment intent.
Risks
- The document certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating the risk of an activist investor or hostile takeover attempt from this specific holder.
Future Outlook
NA
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
This filing indicates a significant passive investment by a major financial institution in a biotechnology or pharmaceutical company, which is a common occurrence in the investment landscape as large funds diversify their portfolios.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Attorney-in-fact for The Goldman Sachs Group, Inc. | Abhishek V, Kateryna Osmachko, Ameen Soetan, Kshama Mishra, Papa Lette, Sunaina Kapoor, and Andrzej Szyszka (from Feb 9, 2024 POA) | Papa Lette, Akash Keshari, Regina Chan, Andrzej Szyszka, Ameen Soetan, Rahail Patel, Santosh Vinayagamoorthy, Sadhiya Raffique, Matthew Pomfret, Abhishek Vishwanathan, Mariana Audeves, Veronica Mupazviriwo, Elizabeth Novak and Sam Prashanth | 2024-07-29 | Superseded previous Power of Attorney |
| Attorney-in-fact for Goldman Sachs & Co. LLC | Abhishek V, Kateryna Osmachko, Ameen Soetan, Kshama Mishra, Papa Lette, Sunaina Kapoor, and Andrzej Szyszka (from Dec 1, 2023 POA) | Papa Lette, Akash Keshari, Regina Chan, Andrzej Szyszka, Ameen Soetan, Rahail Patel, Santosh Vinayagamoorthy, Sadhiya Raffique, Matthew Pomfret, Abhishek Vishwanathan, Mariana Audeves Martinez, Veronica Mupazviriwo, Elizabeth Novak and Sam Prashanth | 2024-10-01 | Superseded previous Power of Attorney |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | The Goldman Sachs Group, Inc. updated its Power of Attorney, superseding the previous one dated February 9, 2024, and appointing new or re-affirming existing attorneys-in-fact for SEC filings. | 2024-07-29 | Streamlines the process for authorized individuals to execute SEC filings on behalf of The Goldman Sachs Group, Inc. |
| Power of Attorney Update | Goldman Sachs & Co. LLC updated its Power of Attorney, superseding the previous one dated December 1, 2023, and appointing new or re-affirming existing attorneys-in-fact for SEC filings. | 2024-10-01 | Streamlines the process for authorized individuals to execute SEC filings on behalf of Goldman Sachs & Co. LLC. |
Stakeholder Impact
- Shareholders may view the investment by Goldman Sachs as a positive signal, potentially increasing investor confidence and interest in Silexion Therapeutics Corp.
Key Dates
| Date | Description |
|---|---|
| 2023-12-01 | Previous Power of Attorney granted by Goldman Sachs & Co. LLC was superseded. |
| 2024-02-09 | Previous Power of Attorney granted by The Goldman Sachs Group, Inc. was superseded. |
| 2024-07-29 | Date of signing of the Power of Attorney for The Goldman Sachs Group, Inc. |
| 2024-10-01 | Date of signing of the Power of Attorney for Goldman Sachs & Co. LLC. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G statement (ownership snapshot date). |
| 2025-01-28 | Date of signing of the Schedule 13G statement and Joint Filing Agreement. |
| 2025-07-29 | Expiration date of the Power of Attorney for The Goldman Sachs Group, Inc. |
| 2025-10-01 | Expiration date of the Power of Attorney for Goldman Sachs & Co. LLC. |
Keywords
Silexion Therapeutics Corp., Goldman Sachs Group Inc., Goldman Sachs & Co. LLC, Schedule 13G, Beneficial Ownership, SEC Filing, Ordinary Shares, Institutional Investor, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.